Encompass Health Corporation filed its quarterly report on Form 10-Q with the Securities and Exchange Commission on November 3, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Shares outstanding: The company reported 98,123,613 shares of common stock outstanding, net of treasury shares, as of October 22, 2026.
  • Reporting period: The quarterly report covers the period ended September 30, 2026.
  • Filer classification: Encompass Health is classified as a large accelerated filer under Exchange Act Rule 12b-2.
  • Exchange listing: Common stock is listed on the New York Stock Exchange under the trading symbol EHC, with a par value of $0.01 per share.
  • Commission file number: The registrant carries Commission File Number 001-10315.
  • Reimbursement concentration: According to the filing, the company is "highly concentrated in our primary line of business, particularly with respect to Medicare regulations and reimbursement."

Encompass Health's Third-Quarter 2026 Disclosure: Operations and Risk Factors

Encompass Health Corporation (NYSE:EHC), headquartered at 9001 Liberty Parkway, Birmingham, Alabama 35242, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing identifies the company as a Delaware-incorporated entity with IRS Employer Identification Number 63-0860407. The registrant confirmed it has filed all required reports during the preceding 12 months and has submitted all required Interactive Data Files electronically.

The filing's forward-looking statements section, which the company cautions are "necessarily estimates based upon current information," identifies a range of risks tied to Medicare and Medicaid reimbursement. Among them, the company disclosed that "reductions or delays in, or suspension of, reimbursement for our services by governmental or private payors, including our inability to obtain and retain favorable arrangements with third-party payors, could decrease our revenues." The filing also notes that disruption to Medicare and Medicaid operations resulting from a federal government shutdown "could delay reimbursements for care and impede some regulatory processes, such as provider enrollment."

Additional risks cited include potential changes stemming from the Inpatient Rehabilitation Facility Review Choice Demonstration, the Transforming Episode Accountability Model, value-based episodic payment models, and "the introduction of site neutral payments or case-mix weightings across post-acute settings." The company further noted that shifts in payor mix, including movement toward Medicare Advantage providers that "limit patient access to inpatient rehabilitation," could reduce volumes, revenues, or profitability. The filing's financial statements and management's discussion are described as unaudited for the quarterly period.

What Was Disclosed

Encompass Health filed a Form 10-Q for the quarter ended September 30, 2026, reporting 98,123,613 shares outstanding as of October 22, 2026, and outlining a broad set of regulatory and reimbursement risks affecting its inpatient rehabilitation business.